UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________ FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-08089 DANAHER CORPORATION (Exact name of registrant as specified in its charter) Securities Reg ...

Danaher Corporation (NYSE:DHR) Q4 2021 Results Conference Call January 27, 2022 8:00 AM ET Company Participants Matthew Gugino - Vice President of Investor Relations Rainer Blair - President and Chief Executive Officer Matt McGrew - Executive Vice President and Chief Financial Officer John Bedford - Director of Investor Relations Conference Call Participants Tycho Peterson - JPMorgan Michael Ryskin - Bank of America Vijay Kumar - Evercore Scott Davis - Melius Research Dan Brennan - Cowen Jack Meehan - Nephr ...

Danaher Corporation (NYSE:DHR) JPMorgan 40th Annual Healthcare Conference Call January 11, 2022 11:15 AM ET Company Participants Rainer Blair - President and Chief Executive Officer Conference Call Participants Tycho Peterson - J.P. Morgan Tycho Peterson Morning, everybody. I'm Tycho Peterson from the life sciences team. It's my pleasure to introduce our next company this morning, Danaher. Just a quick reminder for people that have questions, you can submit questions through the Ask a Question function on t ...

Danaher Corporation Conference Call Summary Company Overview - **Company**: Danaher Corporation (NYSE:DHR) - **Date**: December 1, 2021 - **Participants**: Rainer Blair (CEO), Matt McGrew (CFO), Vijay Kumar (Evercore ISI) Key Industry Insights - **COVID-19 Testing**: Danaher's Cepheid tests can detect the Omicron variant, indicating strong product performance in the face of new variants [4][8] - **Business Impact from COVID-19**: No material impact from lockdowns in Europe has been observed on Danaher's business [6] - **Base Business Performance**: High single-digit growth is expected for the base business, supported by strong performance trends and market share gains [8][12] Financial Performance - **Q4 Guidance**: The guidance for Q4 reflects strong base business performance, with a two-year stack growth of 6-7%, which is 100 basis points higher than pre-pandemic levels [8][33] - **COVID Testing Demand**: Demand for COVID testing remains high, with expectations of shipping 16 million tests in Q4 [10][45] - **Order Book**: Danaher has a strong order book of $2 billion for vaccines and therapeutics, with 85% attributed to vaccines [19][21] Growth Drivers - **Biopharma Sector**: The biopharma segment is expected to grow at a high single-digit rate, with potential for low double-digit growth in the short term due to increased funding and market demand [16][17] - **Aldevron Acquisition**: The acquisition of Aldevron is seen as a strategic move to enhance Danaher's capabilities in genomic medicine, with expectations of over 20% growth in this segment [28][31] - **Infrastructure Investments**: The macro environment remains strong, with infrastructure improvements expected to benefit Danaher's environmental and applied solutions segment [12][34] Market Position and Strategy - **Installed Base Growth**: Danaher has nearly doubled its installed base since 2019, positioning itself as a leader in molecular diagnostics [43] - **ESG Commitment**: Danaher is focused on environmental, social, and governance (ESG) initiatives, with specific targets for diversity and sustainability metrics [55][56] - **M&A Strategy**: Danaher is actively pursuing acquisitions, with a robust pipeline of potential assets that align with its strategic goals [62] Financial Outlook - **Free Cash Flow**: Danaher aims for a free cash flow conversion ratio of around 100%, with expectations of maintaining this level in the near term [64] - **Pricing Strategy**: The company is implementing price increases of approximately 150 basis points, which is higher than historical trends, to manage inflationary pressures [41][39] Conclusion - Danaher Corporation is well-positioned for continued growth in the biopharma and diagnostics sectors, supported by strong demand for COVID testing and strategic acquisitions. The company is focused on maintaining its competitive edge through innovation, market share gains, and a commitment to ESG principles.

Danaher Corporation (NYSE:DHR) Q3 2021 Earnings Conference Call October 21, 2021 8:00 AM ET Company Participants Rainer Blair – President and CEO Matthew Gugino – Vice President of Investor Relations Matt Mc Grew – Executive Vice President and CFO John Bedford – Director of Investor Relations Conference Call Participants Tycho Peterson – J.P. Morgan Vijay Kumar – Evercore ISI Derik De Bruin – Bank of America Scott Davis – Melius Research Dan Brennan – Cowen Jack Meehan – Nephron Matt Sykes – Goldman Sachs L ...

Danaher Corporation (NYSE:DHR) Q2 2021 Results Earnings Conference Call July 22, 2021 8:00 AM ET Company Participants Matthew Gugino - Vice President, Investor Relations and FP&A Rainer Blair - President and Chief Executive Officer Matt McGrew - Executive Vice President and Chief Financial Officer Conference Call Participants Tycho Peterson - J.P. Morgan Michael Ryskin - Bank of America Merrill Lynch Vijay Kumar - Evercore ISI Scott Davis - Melius Research Doug Schenkel - Cowen and Company Daniel Leonard - ...